Stockscreener 앱 받기
2.19
9.13%
-0.22
시간 외 거래:
2.21
0.02
+0.91%
전일 마감가:
$2.41
열려 있는:
$2.4
하루 거래량:
4.15M
Relative Volume:
1.03
시가총액:
$772.92M
수익:
$38.03M
순이익/손실:
$-146.40M
주가수익비율:
-4.2115
EPS:
-0.52
순현금흐름:
$-121.38M
1주 성능:
-15.44%
1개월 성능:
+4.78%
6개월 성능:
-19.49%
1년 성능:
-45.66%
1일 변동 폭
$2.18
$2.40
1주일 범위
$2.18
$2.64
52주 변동 폭
$1.8906
$4.3398
앱셀레라바이오로직스 Stock (ABCL) Company Profile
명칭
Abcellera Biologics Inc
전화
(604) 559-9005
주소
2215 YUKON STREET, VANCOUVER
ABCL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
2.19 | 772.92M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
앱셀레라바이오로직스 Stock (ABCL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-20 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2024-02-22 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Overweight |
| 2023-11-06 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-10-13 | 재개 | Piper Sandler | Overweight |
| 2023-02-28 | 개시 | Cowen | Outperform |
| 2022-12-15 | 개시 | Goldman | Buy |
| 2022-11-16 | 개시 | Truist | Buy |
| 2021-12-21 | 개시 | The Benchmark Company | Buy |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-01-05 | 개시 | BMO Capital Markets | Outperform |
| 2021-01-05 | 개시 | Berenberg | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Outperform |
| 2021-01-05 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | Stifel | Buy |
모두보기
앱셀레라바이오로직스 주식(ABCL)의 최신 뉴스
Abcellera at Bloom Burton: Strategic Shift in Biotech Development By Investing.com - Investing.com UK
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 - BioSpace
AbCellera (ABCL) Unveils Promising Preclinical Results for T-Cel - GuruFocus
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x C - GuruFocus
AbCellera reports promising preclinical TCE cancer therapy data - Investing.com
AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025 | ABCL Stock News - GuruFocus
Is AbCellera Biologics Inc. (ABCL) the Best Canadian Penny Stock to Invest in Now? - Insider Monkey
AbCellera Stock: Attractively Priced, But A Catalyst Is Needed (NASDAQ:ABCL) - Seeking Alpha
KeyBanc Increases Price Target for AbCellera (ABCL) Amidst Economic Concerns | ABCL Stock News - GuruFocus
AbCellera (ABCL) to Engage in Upcoming Investor Conferences - GuruFocus
AbCellera (ABCL) to Release Q1 2025 Financial Results on May 8 - GuruFocus
Top Insider Buys Highlight for the Week of Dec. 18 - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June | ABCL Stock News - GuruFocus
AbCellera to Participate at Upcoming Investor Conferences in May and June - Business Wire
AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025 - BioSpace
Abcellera stock hits 52-week low at $2.1 amid market challenges - Investing.com India
Abcellera stock hits 52-week low at $2.1 amid market challenges By Investing.com - Investing.com South Africa
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025 - Yahoo Finance
AbCellera at KeyBanc Forum: Strategic Moves in Antibody Discovery By Investing.com - Investing.com UK
AbCellera Stock: Burning Cash, Searching For 'Blockbusters' (NASDAQ:ABCL) - Seeking Alpha
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earni - GuruFocus.com
Thermopylae holdings acquires $742,242 in AbCellera shares By Investing.com - Investing.com South Africa
Thermopylae holdings acquires $742,242 in AbCellera shares - Investing.com India
Abcellera stock hits 52-week low at $2.20 amid market challenges - Investing.com Australia
AbCellera biologics director John Montalbano acquires $57,499 in shares By Investing.com - Investing.com South Africa
AbCellera biologics director John Montalbano acquires $57,499 in shares - Investing.com India
Independent Non-Employee Director of AbCellera Biologics Picks Up 66% More Stock - Simply Wall St
Ambarella, Builders Firstsource, Sherwin-Williams, AutoZone, AbCellera: Stock Moves That Shocked the Market - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares By Investing.com - Investing.com India
Director Makes Bold Move with Major Stock Purchase in AbCellera Biologics - TipRanks
Abcellera Biologics director Montalbano buys $140,568 in shares - Investing.com
Q1 Earnings Estimate for ABCL Issued By Bloom Burton - Defense World
Sanctuary Advisors LLC Decreases Stake in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics’ (ABCL) Hold Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Hold on AbCellera stock, no price target change - Investing.com
Benchmark maintains Hold on AbCellera stock, no price target change By Investing.com - Investing.com UK
Stifel Nicolaus Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - MarketBeat
AbCellera Biologics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
AbCellera Biologics (NASDAQ:ABCL) Reaches New 52-Week Low on Analyst Downgrade - MarketBeat
앱셀레라바이오로직스 (ABCL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
3.66%
자본화:
|
볼륨(24시간):